Ascendent Capital invests over $7m in China’s BioChain

Greater China-focused private equity firm Ascendent Capital Partners has invested RMB50 million ($7.34 million) in BioChain Beijing, a subsidiary of integrated bio and data technology firm Team Curis Group with labs in China and the US.

Continue reading this story with a subscription to DealStreetAsia.


Contact us for corporate subscriptions at